Exchange: NASDAQ Sector: Healthcare Industry: Health Information Services
Current Signal: SELL (auto-tracking)
0.19% $0.691
America/New_York / 7 mai 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 53.34 mill |
EPS: | -0.900 |
P/E: | -0.770 |
Earnings Date: | Jun 11, 2024 |
SharesOutstanding: | 77.19 mill |
Avg Daily Volume: | 1.981 mill |
RATING 2024-05-07 |
---|
C |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Strong Buy | |
Return On Asset: | Strong Sell | |
DE: | Strong Sell | |
P/E: | Sell | |
Price To Book: | Strong Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.770 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
0x |
Company: PE -0.770 | industry: PE -4.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 0.585 - 0.797 ( +/- 15.34%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-24 | Icahn School Of Medicine At Mount Sinai | Buy | 9 360 374 | Ordinary Shares |
2023-11-20 | Coste Catherine | Buy | 95 000 | Employee Stock Option (right to buy) |
2023-11-20 | Levangie Daniel J | Buy | 95 000 | Employee Stock Option (right to buy) |
2023-11-20 | Parikh Chirag R. | Buy | 95 000 | Employee Stock Option (right to buy) |
2023-11-20 | Mills Christopher | Buy | 95 000 | Employee Stock Option (right to buy) |
INSIDER POWER |
---|
84.35 |
Last 27 transactions |
Buy: 12 713 670 | Sell: 1 641 743 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $0.691 (0.19% ) |
Volume | 0.235 mill |
Avg. Vol. | 1.981 mill |
% of Avg. Vol | 11.85 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 13 - 10:20 | buy | $1.070 | N/A | Active |
---|
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is headquartered in New York, New York.